General
Preferred name
MITOXANTRONE
Synonyms
MITOXANTRONE HYDROCHLORIDE ()
MITOXANTRONE DIHYDROCHLORIDE ()
CL 232325 ()
CL-232325 ()
DHAQ ()
Novantron ()
Novantrone ()
mitozantrone ()
Mitoxantrone 2HCl ()
NSC-301739 ()
mitozantrone dihydrochloride ()
Mitoxantrone HCl ()
Mitoxantrone 2HCl ()
Dhaq diacetate ()
MITOXANTRONE70476-82-3 ()
Mitoxantrone (dihydrochloride) ()
Mitozantrone (dihydrochloride) ()
NSC 301739 (dihydrochloride) ()
NSC 301739 ()
NSC-301739 2HCl ()
Mitoxantrone (NSC-301739)?2HCl ()
MitoxantroneMitozantroneNovantroneDHAQDihydroxyanthraquinoneMitoxantrone (free base)9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl] amino]-MitroxoneMitoxantrone hydrochloride ()
Mitoxantrone (hydrochloride) ()
CL-232315 ()
Mitoxantrone Dihydrochloride ()
CL 232,315 ()
Mitoxantrone Dihcl ()
Mitoxantrona ()
Misostol ()
NSC-279836 ()
Mitoxantrone-d8 ()
P&D ID
PD004112
CAS
70476-82-3
65271-80-9
137635-96-2
70711-41-0
1189974-82-0
Tags
available
probe
drug
nuisance
Approved by
FDA
First approval
1987
Drug indication
Non-hodgkin lymphoma
Lymphoma
Neoplasm
Solid tumour/cancer
Drug Status
approved
investigational
Max Phase
4.0
Probe info
Probe type
P&D approved
calculated probe
Probe selectivity
protein-selective
Probe sources
Probe targets
[[ compound.targets[t].gene_name ]]
Probe control
Probe control not defined
Orthogonal probes
7
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Mitoxantrone dihydrochloride is a potent topoisomerase II inhibitor. Mitoxantrone dihydrochloride also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 ¦ÌM. Mitoxantrone dihydrochloride induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone dihydrochloride shows antitumor activity[1][2][3][4]. Mitoxantrone dihydrochloride also has anti-orthopoxvirus activity with EC50s of 0.25 ¦ÌM and and 0.8 ¦ÌM for cowpox and monkeypox, respectively[5].
PRICE
29
DESCRIPTION
Marketed formulations may contain mitoxantrone hydrochloride (PubChem CID 5458171).
(GtoPdb)
PRICE
29
DESCRIPTION
Mitoxantrone is a potent topoisomerase II inhibitor. Mitoxantrone also inhibits protein kinase C (PKC) activity with an IC50 of 8.5 ¦ÌM. Mitoxantrone induces apoptosis of B-CLL (B-chronic lymphocytic leukaemia) cells. Mitoxantrone shows antitumor activity[1][2][3][4]. Mitoxantrone also has anti-orthopoxvirus activity with EC50s of 0.25 ¦ÌM and and 0.8 ¦ÌM for cowpox and monkeypox, respectively[5].
DESCRIPTION
Selective CYP3A4 inhibitor
(Tocris Bioactive Compound Library)
DESCRIPTION
DNA synthesis inhibitor
(LOPAC library)
DESCRIPTION
Mitoxantrone is a chemotherapeutic agent used for the treatment of secondary progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis. Mitoxantrone is a DNA-reactive agent that intercalates into deoxyribonucleic acid through hydrogen bonding, causes crosslinks and strand breaks.
(Enamine Bioactive Compounds)
DESCRIPTION
Mitoxantrone dihydrochloride (NSC-301739) is the hydrochloride salt of an anthracenedione antibiotic with antineoplastic activity. It is a type II topoisomerase inhibitor.
(TargetMol Bioactive Compound Library)
DESCRIPTION
Mitoxantrone (mitozantrone) is an anthracenedione antibiotic with antineoplastic activity. Mitoxantrone intercalates into and crosslinks DNA, thereby disrupting DNA and RNA replication. This agent also binds to topoisomerase II, resulting in DNA strand breaks and inhibition of DNA repair. Mitoxantrone is less cardiotoxic compared to doxorubicin.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
52
Organisms
10
Compound Sets
37
A Collection of Useful Nuisance Compounds (CONS) for Interrogation of Bioassay Integrity
CeMM library of unique drugs (CLOUD)
ChEMBL Approved Drugs
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMatrix
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LINCS compound set
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
NCATS Inxight Approved Drugs
NIH Approved Oncology Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Nuisance compounds in cellular assays
Prestwick Chemical Library
Probe Miner (suitable probes)
ReFrame library
Selleckchem Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
ZINC Tool Compounds
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
90
Molecular Weight
444.2
Hydrogen Bond Acceptors
10
Hydrogen Bond Donors
8
Rotatable Bonds
12
Ring Count
3
Aromatic Ring Count
2
cLogP
-0.14
TPSA
163.18
Fraction CSP3
0.36
Chiral centers
0.0
Largest ring
6.0
QED
0.14
Structural alerts
3
Intercalation
Nuisance compounds
anthranil_one_A(38)
c:1:c:c:c:c(:c:1-[#7&!H0;!H1,!$([#7]-[#6]=[#8])])-[#6](-[#6]:[#6])=[#8]
PAINS Family B
quinone_A(370)
[!#6&!#1]=[#6]1[#6]=,:[#6][#6](=[!#6&!#1])[#6]=,:[#6]1
PAINS Family A
Related compounds
Custom attributes
(extracted from source data)
MOA
Topoisomerase inhibitor
Inhibitor
Target
Tyrosine-protein kinase Fyn
DNA topoisomerase II alpha
DNA
PKC
Topo II
Topoisomerase
TOP2A
Apoptosis
Endogenous Metabolite
Orthopoxvirus
Apoptosis related,COVID-19,PKC,Topoisomerase
Primary Target
DNA Topoisomerases
Indication
multiple sclerosis, prostate cancer, acute myeloid leukemia (AML)
Disease Area
neurology/psychiatry, oncology, hematologic malignancy
Pathway
Chromatin/Epigenetic
Cytoskeletal Signaling
DNA Damage/DNA Repair
Anti-infection
Cell Cycle/DNA Damage
Epigenetics
Metabolic Enzyme/Protease
TGF-beta/Smad
Therapeutic Class
Anticancer Agents
Analgesics
Nuisance MOA
Intercalation
Targets
Topoisomerase II
Protein kinase C
Source data
